Internal Medicine, Endocrinology, Diabetes, & Metabolism · Tampa, FL
NPI
1194892141
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
9260 Bay Plaza Blvd, Suite 502
Tampa, FL, 33619
Phone (813) 676-0234
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
762 services
Medicare patients, 2024
373
Average age 73
Drug cost, 2024
$2.5M
6,597 prescriptions
Company payments, 2025
$11K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew D Henry was code 99214 (office e&m - established), 707 times for 359 patients. In total Andrew D Henry billed 762 services in 4 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 707 | 359 | $79.66 | $56K |
| 99204 Office E&M - New | Office | 36 | 36 | $123.27 | $4,438 |
| 99205 Office E&M - New | Office | 18 | 18 | $141.22 | $2,542 |
By year: 2022 $71K for 806 services; 2023 $71K for 844 services; 2024 $63K for 762 services.
Medicare prescription drug claims, 2024
In 2024, the drug Andrew D Henry prescribed most often to Medicare patients was Metformin Hcl, with 409 prescriptions and refills. In total Andrew D Henry wrote 6,597 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metformin Hcl Generic | 409 | 1,058 | 128 | $3,188 |
| Levothyroxine Sodium Generic | 388 | 1,084 | 122 | $3,210 |
| Ozempic Semaglutide | 309 | 536 | 80 | $475K |
| Glimepiride Generic | 284 | 798 | 88 | $3,419 |
| Synthroid Levothyroxine Sodium | 275 | 729 | 79 | $28K |
| Atorvastatin Calcium Generic | 259 | 697 | 75 | $2,356 |
| Mounjaro Tirzepatide | 190 | 248 | 36 | $263K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 185 | 480 | 68 | $49K |
| Rosuvastatin Calcium Generic | 185 | 492 | 57 | $2,208 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 145 | 310 | 53 | $16K |
| Tresiba Flextouch U-100 Insulin Degludec | 140 | 324 | 38 | $255K |
| Lisinopril Generic | 114 | 285 | 31 | $882 |
| Methimazole Generic | 103 | 240 | 33 | $1,020 |
| Farxiga Dapagliflozin Propanediol | 99 | 204 | 23 | $115K |
| Humalog Kwikpen U-100 Insulin Lispro | 95 | 250 | 30 | $43K |
Brand drugs: 2,886 claims; generic drugs: 3,142 claims; opioid claims: 40.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew D Henry $11K ($11K in general payments such as food, travel and fees) from 19 companies. The largest payer was Lilly USA, LLC with $6,357.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 14 | $6,357 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $2,666 |
| Amgen Inc. AMGN | 5 | $326 |
| Corcept Therapeutics CORT | 12 | $299 |
| Xeris Pharmaceuticals, Inc. | 9 | $286 |
| Novo Nordisk Inc NVO | 13 | $276 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $134 |
| Mannkind Corporation MNKD | 4 | $112 |
| Globus Medical, Inc. GMED | 2 | $95.26 |
| Sequel Med Tech, LLC | 2 | $39.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.